GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in Type 2 Diabetes
Tran S, Retnakaran R, Zinman B, Kramer CK. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl-4 inhibitors for the management of diabetes : a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2018;20 Suppl 1:68-76.
Treatment with glucagon-like peptide-1 (GLP-1) agonists is associated with greater reductions in glycated hemoglobin (HbA1c) and body weight than dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes, according to a meta-analysis published in Diabetes, Obesity and Metabolism.
Investigators systematically searched randomized controlled trials (RCTs) that compared GLP-1 agonists with…